FORMULATION ARTICLES
-
![Abstract Modern-GettyImages-490280002]( "Rethinking The \"3:1 Rule\" In LNP Production")
Rethinking The "3:1 Rule" In LNP ProductionA new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.
-
![Tumor microenvironment, cancer cells, t-cells, nanoparticles-GettyImages-1449007926]( "Emerging RNA Delivery Strategies For Solid Tumor Oncology")
Emerging RNA Delivery Strategies For Solid Tumor OncologyRNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.
-
![path of exponential growth-GettyImages-2229192052]( "Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing")
Trends In Oligo Scale-Up & Delivery & How They're Impacting ManufacturingHere, a panel of experts at the RNA Leaders Conference give a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.”
-
![Researcher at work in DNA genetic laboratory, virus and pathogen detection-GettyImages-1346857647]( "Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next")
Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes NextNeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.
-
![Liposome is releasing siRNA, mRNA, or RNA-GettyImages-1656071904]( "Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics")
Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA TherapeuticsWhile LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.
-
![Healthcare collaboration-GettyImages-1724755569]( "Translating An Early-Stage mRNA Therapeutic Into The Clinic")
Translating An Early-Stage mRNA Therapeutic Into The ClinicIn the following Q&A, Ethris CMO Thomas Langenickel shares some of his biggest questions and observations about the evolving mRNA therapeutics space that are the most impactful in translating early-stage RNA candidates into the clinic — particularly when that drug product boasts a novel formulation.
FORMULATION VIDEOS
mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.
Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.
How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation?
Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![mRNA GettyImages-1356994684]( "mRNA Manufacturing And Formulation")
From fermentation to formulation, mRNA manufacturing requires a toolbox of technologies, services, and expertise. Explore our portfolio of solutions for making, purifying, and formulating mRNA.
-
![GettyImages-2149039456 lab, research, microscope]( "Development And Optimization Of LNP Formulations")
The production of lipid nanoparticles (LNPs) is a process that demands robustness, scalability, and reproducibility. Examine the impact of key operational parameters on the efficacy of LNPs.
-
![GettyImages-1194781834-cell]( "mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations")
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
-
![Covid Vaccine Production Line GettyImages-1336518535]( "Analytics And Bioassays Can Safely Fast-Track mRNA-LNP Drug Development")
One main mRNA technology challenge is the formulation of delivery systems like lipid nanoparticles (LNPs). Learn about evading impurities in lipids, the future of mRNA-based genomic medicines, and more.
-
![Lipid nanoparticle mRNA vaccine-GettyImages-1418152448]( "Advancing A LNP Formulation To Clinical And Commercial Manufacturing")
Lipid selection impacts the final LNP drug product and the LNP process. Review critical quality considerations for lipids and the process requirements for successful commercial-scale manufacturing.
-
![Scientist In Lab GettyImages-1354172647]( "Boost LNP Drug Potency With Optimized Delivery Formulations")
Lipid nanoparticles (LNPs) function as a drug delivery system for nucleic acids. Learn about the biomedical applications of LNPs as well as the anatomy, formulation optimization, and safety of LNPs.
-
![iStock-1295693740-covid-coronavirus-vaccine-mrna]( "Developing A Scalable RNA-LNP Drug Product For Clinical Translation")
Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.
